Bhatt Darshak K, Wekema Lieske, Carvalho Barros Luciana Rodrigues, Chammas Roger, Daemen Toos
Department of Medical Microbiology and Infection Prevention, University Medical Center Groningen, University of Groningen, 9713 AV Groningen, the Netherlands.
Center for Translational Research in Oncology, Instituto do Câncer do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, CEP 01246-000, Brazil.
Mol Ther Oncolytics. 2021 Oct 5;23:239-253. doi: 10.1016/j.omto.2021.09.008. eCollection 2021 Dec 17.
Several onco-virotherapy candidates have been developed and clinically evaluated for the treatment of cancer, and several are approved for clinical use. In this systematic review we explored the clinical impact of onco-virotherapy compared to other cancer therapies by analyzing factors such as trial design, patient background, therapy design, delivery strategies, and study outcomes. For this purpose, we retrieved clinical studies from three platforms: ClinicalTrials.gov, PubMed, and EMBASE. We found that most studies were performed in patients with advanced and metastatic tumors, using a broad range of genetically engineered vectors and mainly administered intratumorally. Therapeutic safety was the most frequently assessed outcome, while relatively few studies focused on immunological antitumor responses. Moreover, only 59 out of 896 clinical studies were randomized controlled trials reporting comparative data. This systemic review thus reveals the need of more, and better controlled, clinical studies to increase our understanding on the application of onco-virotherapy either as a single treatment or in combination with other cancer immunotherapies.
已经开发了几种用于癌症治疗的肿瘤病毒疗法候选药物并进行了临床评估，其中几种已获批用于临床。在这项系统评价中，我们通过分析试验设计、患者背景、治疗设计、给药策略和研究结果等因素，探讨了肿瘤病毒疗法与其他癌症疗法相比的临床影响。为此，我们从三个平台检索了临床研究：ClinicalTrials.gov、PubMed和EMBASE。我们发现，大多数研究是在晚期和转移性肿瘤患者中进行的，使用了广泛的基因工程载体，主要通过瘤内给药。治疗安全性是最常评估的结果，而相对较少的研究关注免疫抗肿瘤反应。此外，896项临床研究中只有59项是报告比较数据的随机对照试验。因此，这项系统评价表明，需要进行更多、控制更好的临床研究，以增进我们对肿瘤病毒疗法作为单一治疗或与其他癌症免疫疗法联合应用的理解。
